Molecular Profile Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

Profile Name STK11 loss
Gene Variant Detail

STK11 loss (loss of function)

Relevant Treatment Approaches mTOR Inhibitor mTORC1 Inhibitor


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
STK11 loss Advanced Solid Tumor no benefit mTOR Inhibitor Metformin Preclinical - Cell culture Actionable In a preclinical study, Glucophage (metformin) was unable to inhibit cancer cell growth in cancer cell lines with biallelic loss of STK11 (PMID: 17062558, PMID: 18006825). 18006825 17062558
STK11 loss lung cancer resistant unspecified PD-1 antibody Preclinical Actionable In a preclinical study, PD-1 antibodies were ineffective in treating Stk11 (also known as Lkb1) deficient lung tumors in mice (PMID: 26833127). 26833127
STK11 loss lung non-small cell carcinoma no benefit mTOR Inhibitor Vistusertib Clinical Study - Cohort Actionable In a Phase II trial (NLMT), Vistusertib (AZD2014) treatment resulted in an observed objective response rate (ORR) of 0% (0/17), durable clinical benefit rate (DCBR) of 12% (2/17), and medial progression-free survival (PFS) of 2.3 months in patients with non-small cell lung cancer harboring STK11 loss, with Bayesian posterior probability for OR and DCBR of <0.01 and 0.06, respectively, thus the cohort was closed due to futility (PMID: 32669708, NCT02664935). 32669708
STK11 loss lung non-squamous non-small cell carcinoma no benefit Avelumab + Talazoparib Phase II Actionable In a Phase II trial (SWOG S1900C, LUNG-MAP sub-study), Talzenna (talazoparib) and Bavencio (avelumab) combination therapy did not meet the efficacy threshold in patients with advanced or recurrent non-squamous non-small cell lung cancer harboring STK11 pathogenic mutations or biallelic loss, resulting in an objective response rate of 2% (1/47) and a disease control rate at 12 weeks of 40% (17/47) (J Clin Oncol 40, no. 16_suppl (June 01, 2022) 9060; NCT04173507). detail...